Cai Jing Wang·2026-02-24 08:40Group 1 - The core point of the article is that Frontier Biotech has entered into an exclusive licensing agreement with GlaxoSmithKline (GSK) for two small interfering RNA (siRNA) pipeline products, granting GSK global rights for development, manufacturing, and commercialization [1] - One of the candidate drugs has entered the Investigational New Drug (IND) application stage, while the other is in the preclinical stage [1] - Frontier Biotech will receive an upfront payment of $40 million and a near-term milestone payment of $13 million, with potential additional payments of up to $950 million based on successful development, regulatory, and commercialization milestones [1] Group 2 - Frontier Biotech will be responsible for early development work on the two products, including advancing one product through Phase I clinical trials in China and completing IND supportive research for the other product [1] - GSK will handle all global clinical development, regulatory submissions, and commercialization activities for both products [1]